Welcome to the e-CCO Library!

P551: Use of preoperative total parenteral nutrition is associated with clinical and laboratory remission in severe active Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Kolonimos*1,2, M. S. Berns1,2, L. Hai Katvan1,2, M. Zelcer1,2, O. A. Hatoum2,3, N. Sakran2,3, I. M. Gralnek1,2, E. Zittan1,2

Created: Friday, 22 February 2019, 9:41 AM
P552 Withdrawal of immunomodulator medications (IM) in children with inflammatory bowel disease on combination therapy of IM and biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Chandrakumar1, M. Carroll2, J. deBruyn3, K. Jacobson4, H. Huynh2, E. Wine2, S. Lawrence4, W. El-Matary5

Created: Thursday, 30 January 2020, 10:12 AM
P552: An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sutton R.1, Wierstra K.2, Ambrosio L.3, Dieleman L.3, Fedorak R.N.3, Halloran B.3, Kroeker K.I.3, Wong K.3, Berga K.-A.4, Huang V.W.*5

Created: Wednesday, 20 February 2019, 10:36 AM
P552: Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease Patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cohen, Y.(1);Fischman, M.(1);Waterman, M.(2);Dolnikov, K.(3);Azzam, Z.S.(3);Ghersin, I.(2)*;
Created: Friday, 14 July 2023, 11:05 AM
P552: Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
Year: 2021
Source: ECCO'21 Virtual
Authors: Xiao, Y.(1);AL Khoury, A.(2);Golovics, P.(3);Kohen, R.(2);Afif, W.(2);Wild, G.(2);Friedman, G.(4);Galiatsatos, P.(4);Hilzenrat, N.(4);Szilagyi, A.(4);Wyse, J.(4);Cohen, A.(4);Bitton, A.(4);Bessissow, T.(4);Lakatos, P.L.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P552: Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Patel1*, J.M. Khalid1, S. Shah2, R. Shah3, A. Berger2

Created: Thursday, 21 February 2019, 9:14 AM
P552: Gastroenterologists’ perceptions on use of medical cannabis for IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Koslowsky*1, A. Bar-Gil Shitrit1, E. Goldin1, B. Mazuz1

Created: Friday, 22 February 2019, 9:41 AM
P552: Higher Serum Ustekinumab Levels Correlate With Higher Rates Of Steroid-Free Deep Remission And Endoscopic Healing In Patients With Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Yarur, A.(1);Ungaro, R.(2);Jain, A.(3);Nunex, L.(1);Spencer, E.(2);Bruss, A.(1);Berens, B.(1);Beniwal-Patel, P.(1);Dervieux, T.(3);Dubinsky, M.(2);
Created: Friday, 11 February 2022, 3:56 PM
P553 Safety of the sequential use of biological therapy in inflammatory bowel disease: Results from a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Moens1,2, V. Ballet1, J. Sabino1,2, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 30 January 2020, 10:12 AM
P553: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P553: Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ghosh, S.(1)*;Long, M.(2);Ott, E.(3);Gasink, C.(3);Baker, T.(4);Godwin, B.(3);Miao, Y.(4);Loftus, E.(5);
Created: Friday, 14 July 2023, 11:05 AM
P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Berger1*, A. Pilch1, J. Ruppert1, F.-P. Armbruster1, J. Stein2,3, K. Farrag2,3

Created: Thursday, 21 February 2019, 9:14 AM
P553: Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ferreiro-Iglesias*1, A. Jardi1, A. Quiroga1, I. Baston1, J. Gonzalez2, J. M. Giraldez2, I. Zarra2, M. J. Lamas2, J. E. Dominguez-Munoz1, M. Barreiro-de Acosta1

Created: Friday, 22 February 2019, 9:41 AM
P553: Factors related to steroid consumption in IBD patients: Evidence from a multicenter Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Barkan, R.(1); Shpoker , L.(2);Abboud, R.(2);Nafrin, S.(3);Ganon , M.(4);Ilsar , T.(4);Volf , T.(5);Markovitch , L.(6);Saban , M.(7);Kagan, I.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P553: Long-term outcomes of seton drainage for perianal fistulizing Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Banayan E., Zagihyan K., Fleshner P.

Created: Wednesday, 20 February 2019, 10:36 AM
P554 Dietary practices and beliefs of patients with inactive ulcerative colitis: A prospective UK study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

Created: Thursday, 30 January 2020, 10:12 AM
P554: Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?
Year: 2021
Source: ECCO'21 Virtual
Authors: SinaDr., M.(1);Pemaj, X.(1);Akshija, I.(2);Hysa, A.(1);Koçollari, A.(1);Prifti, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P554: Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Higgins, P.D.R.(2);Peyrin-Biroulet, L.(3);Sands, B.E.(4);Lee, S.(5);Moses, R.E.(6);Redondo, I.(7)*;Escobar, R.(8);Morris, N.(9);Kobayashi, T.(10);
Created: Friday, 14 July 2023, 11:05 AM
P554: Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Atreja A., Khan S., Otobo E., Rogers J., Ullman T., Grinspan A., Itzkowitz S., Maser E., Cohen B., Colombel J.-F., Sands B.

Created: Wednesday, 20 February 2019, 10:36 AM
P554: Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Palaparthy1*, S. Schmitt2, M.I. Rehman3, C.-H. Cai1, K. Wang1, O. von Richter2

Created: Thursday, 21 February 2019, 9:14 AM